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Our objective was to describe the population pharmacokinetics of fluconazole in a cohort of critically ill nonobese, obese,
and morbidly obese patients. Critically ill patients prescribed fluconazole were recruited into three body mass index (BMI)
cohorts, nonobese (18.5 to 29.9 kg/m2), obese (30.0 to 39.9 kg/m2), and morbidly obese (>40 kg/m2). Serial fluconazole
concentrations were determined using a validated chromatographic method. Population pharmacokinetic analysis and
Monte Carlo dosing simulations were undertaken with Pmetrics. Twenty-one critically ill patients (11 male) were enrolled,
including obese (n 6) and morbidly obese (n 4) patients. The patients mean standard deviation (SD) age, weight,
and BMI were 54 15 years, 90 24 kg, and 31 9 kg/m2, respectively. A two-compartment linear model described the
data adequately. The mean SD population pharmacokinetic parameter estimates were clearance (CL) of 0.95 0.48 li-
ter/h, volume of distribution of the central compartment (Vc) of 15.10 11.78 liter, intercompartmental clearance from
the central to peripheral compartment of 5.41 2.28 liter/h, and intercompartmental clearance from the peripheral to
central compartment of 2.92 4.95 liter/h. A fluconazole dose of 200 mg daily was insufficient to achieve an area under the
concentration-time curve for the free, unbound drug fraction/MIC ratio of 100 for pathogens with MICs of>2 mg/liter in
patients with BMI of>30 kg/m2. A fluconazole loading dose of 12 mg/kg and maintenance dose of 6 mg/kg/day achieved
pharmacodynamic targets for higher MICs. A weight-based loading dose of 12 mg/kg followed by a daily maintenance dose
of 6 mg/kg, according to renal function, is required in critically ill patients for pathogens with a MIC of 2 mg/liter.
Recent decades have seen an increased prevalence in obesityworldwide (1, 2). More than two-thirds of adults in the U.S.
are either overweight or obese, while one-third are obese (3, 4).
Mortality and morbidity are higher in obese patients than non-
obese patients for different types of infections, such as surgical site
infections, community-acquired pneumonia, and peritonitis in
peritoneal dialysis patients (5–8). Optimization of dosing is essen-
tial to minimize the risk of therapeutic failure in these patients.
However, few data are available to guide clinicians for effective
antimicrobial dosing in obese patients.
Moreover, dosing in obese critically ill patients is relatively
unexplored; thus, it is a highly challenging scenario for clinicians
(9, 10). Although only sparse data are available, it is possible that
the altered pharmacokinetics (PK) that occur in critically ill pa-
tients are heightened by the presence of obesity due to concurrent
pathophysiological changes (11, 12). The physiological changes
that are likely to occur in obese compared to nonobese patients
include reduced regional blood flow, increased cardiac output,
and increased fat and lean mass (13). These changes in obese pa-
tients are likely to alter the PK/pharmacodynamics (PK/PD) of
antimicrobials, thereby requiring dosing adjustments to ensure
optimal patient outcomes. As the prevalence of critically ill obese
patients increases, clinicians will face an increasing challenge to
ensure effective antimicrobial therapy.
Fluconazole is a commonly used triazole antifungal in critically
ill patients (14). It is commonly prescribed to treat infections
caused by Candida albicans and Candida tropicalis (14). In healthy
individuals and non-critically ill patients, fluconazole has a favor-
able PK and safety profile and exhibits a long half-life (30 h),
enabling once-daily dosing. Fluconazole is excreted unchanged in
urine, with80% renal clearance. It has low plasma protein bind-
ing (11 to 12%) and a moderate volume of distribution (V), about
0.65 to 0.70 liter/kg (15).
In critically ill nonobese patients, fluconazole PK appears to be
different from that of healthy subjects (16). This is likely due to
organ dysfunction, renal and/or hepatic, as well as fluid shifts and
capillary permeability changes that can alter fluconazole clearance
and V. There is little or no data about the PK of fluconazole in
obese patients, particularly critically ill obese patients. Therefore,
it remains unclear whether standard fluconazole dosing regimens
will provide sufficient drug exposure.
The aim of this prospective study was to describe the popula-
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tion PK of fluconazole in a cohort of critically ill nonobese, obese,
and morbidly obese patients.
MATERIALS AND METHODS
Setting. This was an observational PK study at a tertiary referral intensive
care unit (ICU). Ethical approval was obtained from the local institutional
Human Research Ethics Committee (HREC/14/QRBW/88). Written in-
formed consent was obtained from all participants or from their substi-
tute decision-makers.
Study population. The inclusion criteria for this study were the fol-
lowing: (i) age of 18 years, (ii) receiving fluconazole (prophylaxis or
treatment), and (iii) body mass index (BMI) of18.5 kg/m2. The exclu-
sion criteria were the following: (i) patients on renal replacement therapy
(RRT), (ii) pregnant women, (iii) patients with active bleeding, or (iv)
patients with HIV or hepatitis.
Study protocol. Fluconazole was administered at the direction of the
treating intensivist. Participants were categorized into three groups ac-
cording to their BMI as normal weight (BMI of 18.5 to 29.9 kg/m2), obese
(BMI of 30 to 39.9 kg/m2), and morbidly obese (BMI of 40 kg/m2).
During one dosing interval, blood samples (3 ml) were taken from each
participant to determine plasma fluconazole concentrations at predose, at
30 min and 60 min, and at 2, 3, 4, 5, 6, 8, 12, and 24 h after dose admin-
istration (10 samples for 12-h dosing or 11 samples for 24-h dosing).
Other clinical and demographic data were collected on the day of plasma
sampling, including age, sex, total body weight (TBW), ideal body weight
(IBW), lean body weight (LBW), and BMI (17). Clinical data also were
recorded, including sequential organ failure assessment (SOFA) (18) and
acute physiology and chronic health evaluation II (APACHE II) (19)
scores, as well as serum albumin and creatinine concentrations (SCR) and
CLCR estimated by the Cockcroft-Gault equation (separately using TBW,
LBW, and IBW) (20). Urine samples were also collected over the dosing
interval to determined measured CLCR.
Sample handling, storage, and assay. Blood samples were placed in
an ice bath immediately and centrifuged at 3,000 rpm for 10 min. Plasma
samples were stored at 80°C until bioanalysis. Fluconazole was mea-
sured in plasma by an ultrahigh-performance liquid chromatography-
tandem mass spectrometry (UHPLC-MS/MS) method with a reverse-
phase F5 column on a Shimadzu Nexera2-8030 system. Unknown
samples were assayed in batches alongside calibrators, and quality con-
trols and results were subject to batch acceptance criteria. Plasma (100
l) was spiked with internal standard (voriconazole), and acetonitrile
was added to precipitate proteins. The supernatant was isolated and 1
l injected onto the UHPLC. For the stationary phase, we used a Phe-
nomenex Kinetex F5 column, 50 by 2.1 mm, 1.7 m volume, heated to
30°C. For the mobile phase, we used a 75:25 blend of phase A (0.1%
formic acid in 10 mM ammonium formate) and phase B (0.1% formic
acid in acetonitrile) delivered isocratically at a flow rate of 0.4 ml/min,
producing a typical backpressure of 5,500 lb/in2. Fluconazole (reten-
tion time of 0.67 min) was well separated from voriconazole (retention
time of 3.93 min) in a run time of 5 min. Column eluent was directed
to the mass spectrometer from 0.3 to 4.5 min. Ionization was by posi-
tive-mode electrospray, with fluconazole and voriconazole being mon-
itored at 306.7g238.2 and 350.0g281.1, respectively. The assay method
was validated for linearity, lower limit of quantification, and precision and
accuracy using the FDA and European Medicines Agency (EMA) criteria
for bioanalysis (21). The method was linear from 0.1 to 20 mg/liter. The
precision was within 3.1% and accuracy was within 3.6% at the three levels
tested. The stability of fluconazole in plasma and water stored at 80°C
was validated for 19 months.
Population pharmacokinetic modeling. The plasma fluconazole
concentrations were fitted to one- and two-compartment models using a
nonparametric adaptive grid (NPAG) algorithm within the Pmetrics
package for R (Los Angeles, CA, USA) (22, 23).
Demographic and clinical characteristics that were considered biolog-
ically plausible for affecting fluconazole PK were tested for inclusion as
covariates. Data, including age, sex, TBW, IBW, LBW, BMI, SCR, mea-
sured CLCR, CLCR estimated by Cockcroft-Gault equation (separately us-
ing TBW, LBW, and IBW), albumin levels, and SOFA and APACHE II
scores, were tested. Each of these covariates was plotted against the PK
parameter estimates to assess correlation. Covariates were retained in the
model if they significantly improved the log likelihood (P 0.05) and/or
improved the goodness-of-fit plots.
Model diagnostics.Visual inspection of the observed-predicted (pop-
ulation and individual) concentration scatter plot was undertaken with
the coefficient of determination of linear regression of observed-predicted
values, and the log-likelihood values from each run were used to evaluate
the goodness of fit. Predictive performance evaluation was based on the
means of both prediction error (bias) and bias-adjusted squared predic-
tion error (imprecision) of the population and an individual prediction
model in the central compartment. A visual predictive check using 1,000
simulations was used to evaluate the suitability of the final covariate
model. Additionally, the area under the concentration-time curve (AUC)
was calculated using the Bayesian estimates of the final model.
PTA. Monte Carlo simulations (n  1,000) were performed using
Pmetrics software to determine the probability of target attainment (PTA)
for PK/PD targets of 25 and 100 for ratios of the AUC for the free, un-
bound drug fraction to the MIC (fAUC/MIC) for various measured CLCR
values and patient BMI (24–26). A free fraction of 12% was used for all
simulations.
Fixed fluconazole loading doses (LD) of 200 mg, 400 mg, or 800 mg
delivered intravenously for 12 or 24 h (infusion rate of 200 mg/60 min)
were simulated from 0 to 24 h at three different levels of renal function
(measured CLCR of 30, 50, and 150 ml/min) and three BMI groups of 20,
30, and 40 kg. The PTA for achieving fAUC/MIC of 25 and 100 were
calculated.
Weight-based fluconazole loading doses of 3 mg/kg, 6 mg/kg, 9 mg/kg,
12 mg/kg, and 15 mg/kg from 0 to 24 h for BMI of 30 kg/m2 with measured
CLCR of 50 ml/min were simulated. We also simulated fluconazole main-
tenance doses of 3 mg/kg/day, 6 mg/kg/day, 9 mg/kg/day, 12 mg/kg/day,
and 15 mg/kg/day from 96 to 120 h for BMI of 30 kg/m2 (after a loading
dose of 12 mg/kg on day 1) with three measured CLCR levels of 30, 50, and
150 ml/min.
FTA calculation. The fAUC/MIC data for the susceptible pathogens
C. albicans and C. tropicalis were used according to MIC distributions
from the European Committee for Antimicrobial Susceptibility and Test-
ing (EUCAST) database (25) to determine the fractional target attainment
(FTA). The FTA describes the pharmacodynamic exposure (PTA) of flu-
conazole against a MIC distribution. This FTA threshold was attained
when the value was90%. Susceptible MIC distributions of both patho-
gens (MIC of 2 mg/liter) were used to determine the FTA for directed
therapy.
Statistical analysis. Continuous variables are presented as means
(with standard deviations [SD]) or medians (with interquartile ranges) as
appropriate. Categorical variables are expressed as absolute numbers and
relative frequencies. The Kolmogorov-Smirnov and Shapiro-Wilk tests
were used to test for normality. A one-way analysis of variance (ANOVA)
was used to test for differences in demographic and clinical data between
the BMI categories. Linear regression was used to describe correlations
between patient weight metrics in the three BMI categories with the flu-
conazole volume of distribution in the central compartment (Vc) and
clearance. All statistical analyses were performed using the statistical soft-
ware package IBM-SPSS statistics 22.0 (IBM, New York, USA). A P value
of0.05 was considered statistically significant.
RESULTS
Demographic and clinical data. Twenty-one critically ill patients
(11 male) were enrolled in the study; 11 nonobese, 6 obese, and 4
morbidly obese patients. In total, 215 blood samples were ob-
tained from the participants. The demographics and clinical char-
acteristics of the respective BMI categorizations are shown in
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Table 1. Only patients’ TBW, LBW, and BMI were significantly
different between the three BMI categorizations (P 0.05).
Pharmacokinetic model building. Fluconazole PK was best
described using a two-compartment linear model. The model
goodness of fit was improved by inclusion of the covariates mea-
sured CLCR (normalized to the population mean of 105 ml/min)
for fluconazole clearance and BMI (normalized to 30 kg/m2) for
fluconazole Vc. Furthermore, addition of both resulted in a statis-
tically significant improvement in the log likelihood from the pre-
vious model (P 0.05).
Measured CLCR, Cockcroft-Gault (based on total body weight),
and modified diet in renal disease equations were each tested as
potential covariates for fluconazole clearance. None of these CLCR
measures resulted in a statistically significant decrease in the log
likelihood. However, of these, the lowest log likelihood was asso-
ciated with inclusion of measured CLCR in the model. The addi-
tion of this covariate improved the agreement between the ob-
served and population-predicted concentrations as well as
distribution of observed data within the visual predictive check, so
it was retained in the final model.
Addition of BMI as a descriptor of Vc to the final covariate
model was performed even though there was no positive correla-
tion evident between Vc and BMI. This decision was based on
biological plausibility and because the addition resulted in a clear
improvement of the observed and population-predicted concen-
tration goodness-of-fit plot as well as the visual predictive check
plot.
The final covariate model was TVCL  CL  CLCR/105 and
TVVC  Vc  BMI/30, where TVCL is the typical value of flu-
conazole clearance and TVVc is the typical value of fluconazole
distribution in the central compartment.
The mean	 SD population PK parameter estimates from the
final covariate model are shown in Table 2. The diagnostic plots
and visual predictive check confirmed the appropriateness of the
model as shown in Fig. 1 and 2, respectively. The final covariate
model was for Monte Carlo dosing simulations.
Dosing simulations. Monte Carlo simulations and PTA for
achieving fAUC/MIC of 25 and 100 for fixed 200-mg, 400-mg, and
800-mg daily doses are presented in Table 3. For an fAUC/MIC of
25, the results showed that all morbidly obese patients failed to
achieve the PK/PD target of a MIC of 2 mg/liter at lower flucona-
zole doses (200 mg daily). For higher doses (800 mg daily), there
was failure to achieve an fAUC/MIC of 25 for a MIC of 8 mg/liter.
For an fAUC/MIC of 100, all simulated morbidly obese patients
failed to achieve the PK/PD target for a MIC of 0.5 mg/liter at a
fixed 200-mg daily dose and for a MIC of 2 mg/liter at a fixed
800-mg daily dose.
FTA. The FTA for the different scenarios are shown in Tables 4
and 5. For an fAUC/MIC of 25, all fluconazole dosing regimens
successfully achieved the 90% target for directed therapy (MIC
distribution of2 mg/liter). For an fAUC/MIC of 100, the lower
fluconazole dose (i.e., 200 mg daily) achieved 90% coverage of C.
albicans for directed therapy only in patients in the normal weight
group at the lower measured CLCR (30 and 50 ml/min).
The higher fluconazole dosing regimen (800 mg daily)
achieved 90% coverage of susceptible C. albicans and C. tropicalis
in all BMI groups at different levels of measured CLCR (Fig. 2).
FTAatdifferentfluconazoleweight-based loadingandmain-
tenance doses. The FTA for various weight-based dosing regi-
mens from 0 to 24 h and separately from 96 to 120 h are shown in
Fig. 3 and 4. These data show that a loading dose of at least 12
mg/kg was required for the fAUC/MIC target of 100. Further-
more, a maintenance dose of at least 6 mg/kg/day (TBW) was
required to achieve an fAUC/MIC of 100 (assessed between 96 and
120 h of therapy).
TABLE 1 Demographic and clinical data
Variablea
Mean (SD) value by wt group
P valueAll (n 21) Normal wt (n 11) Obese (n 6) Morbidly obese (n 4)
Age (yr) 54 (15) 55 (18) 53 (15) 54 (7) 0.97
wt (kg) 90 (24) 74 (10) 98.1 (17) 122 (23) 0.001
IBW (kg) 64 (10) 67 (7) 66 (12) 55 (11) 0.09
LBW (kg) 56 (10) 56 (6) 62.5 (11) 47 (10) 0.03
Height (cm) 171 (11) 173 (8) 172 (13) 163 (13) 0.29
Sex (no. [%] male) 11 (52) 7 (64) 3 (50) 1 (25)
BMI (kg/m2) 31 (9) 25 (3) 33 (3) 46 (6) 0.001
SCR (mol/liters) 74 (35) 62 (21) 83 (40) 94 (52) 0.22
Measured CLCR (liters/h) 106 (54) 108 (45) 89 (27) 125 (103) 0.60
CG-TBW (liters/h) 142 (85) 127 (57) 135 (66) 192 (159) 0.43
CG-IBW (liters/h) 102 (52) 113 (47) 89 (40) 90 (84) 0.60
CG-LBW (liters/h) 89 (45) 95 (41) 84 (38) 78 (72) 0.81
SOFA score 5 (2) 5 (2) 6 (3) 3 (1) 0.29
APACHE II score 20 (5) 19 (2) 21 (7) 22 (8) 0.48
a CG-TBW, estimated CLCR using Cockcroft-Gault equation based on total body weight; CG-IBW, estimated CLCR using Cockcroft-Gault equation based on ideal body weight;
CG-LBW, estimated CLCR using Cockcroft-Gault equation based on lean body weight.
TABLE 2 Parameter estimates for fluconazole from the final covariate
two-compartment population PK model
Parametera
Mean value
(SD)
Coefficient of
variation (%) Median
CL (liters/h) 0.95 (0.48) 50.47 0.86
Vc (liters) 15.10 (11.78) 78.07 8.55
KCP (h1) 5.41 (2.28) 42.21 5.42
KPC (h1) 2.92 (4.95) 170.00 1.04
a CL, population clearance of fluconazole; Vc, population volume of distribution of
central compartment; KCP, rate constant for fluconazole distribution from the central
to peripheral compartment; KPC, rate constant for fluconazole distribution from the
peripheral to central compartment.
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DISCUSSION
Key findings. This is the first population PK study of fluconazole
in critically ill nonobese, obese, and morbidly obese patients. Flu-
conazole PK/PD targets of an fAUC/MIC of 
25 (for fungistatic
effect [24]) and of 
100 (for a high probability of cure for Can-
dida spp. with a MIC of up to 2 mg/liter [24]) were both tested due
to the uncertainty of which PK/PD ratios should be targeted
to ensure successful treatment. We found that a fluconazole
FIG 1 Diagnostic plot for the final population pharmacokinetic covariate model. (a) Observed fluconazole concentrations versus population-predicted
fluconazole concentration (R2  0.627). (b) Observed fluconazole concentrations versus individual-predicted fluconazole concentration (R2  0.967). CI,
confidence interval.
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dosing regimen of 200 mg/day was sufficient to achieve the
PK/PD target of an fAUC/MIC of 
25. However, a higher flu-
conazole dosing regimen, 400 mg/day or 800 mg/day, was re-
quired to achieve the higher target of an fAUC/MIC of 
100.
We believe a more accurate approach to dosing may be
achieved through the use of a weight-based approach which
includes a loading dose of 12 mg/kg on day 1 and a mainte-
nance dose guided by measured CLCR.
Relationship with previous papers. Despite the common
use of fluconazole in the ICU, there is a significant shortage of
robust PK studies of this drug for obese critically ill patients.
Lopez and Phillips, in a recent case report of a morbidly obese
patient (BMI of 84.0 kg/m2 [272 kg]) on RRT, reported the use
of a 12-mg/kg fluconazole loading dose (based on LBW) fol-
lowed by a maintenance dose of 6 mg/kg (27–29). The resulting
fAUC was 163.8 mg · h/liter (assuming 11% protein binding),
which would be sufficient to achieve the PK/PD target of an
fAUC/MIC of
25 but not quite the higher PK/PD target of an
fAUC/MIC of
100. In another case report of a morbidly obese
patient (BMI of 48.3 kg/m2; measured CLCR of 125 ml/min),
Cohen et al. reported the use of a 1,200-mg daily dose, admin-
istered as a 6-h infusion, with the resulting measured fAUC of
494.4 mg &3x00B7; h/liter (assuming 11% protein binding).
This dose was sufficient to achieve both the lower and higher
PK/PD targets (30). Both case reports on critically ill patients
support the use of higher-than-standard doses in obese pa-
tients.
In a study of critically ill nonobese patients with normal renal
TABLE 3 Fluconazole PTA at different BMIs, CLCR, and loading dosage regimens
Dose (mg), BMI (kg/m2),
and CLCR (ml/min)
PTA by MIC (mg/liter) and fAUC/MIC ofa:

25 
100
0.12 0.25 0.5 1 2 4 8 16 0.12 0.25 0.5 1 2 4 8 16
200
20
30                
50                
150                
30
30                
50                
150                
40
30                
50                
150                
400
20
30                
50                
150                
30
30                
50                
150                
40
30                
50                
150                
800
20
30                
50                
150                
30
30                
50                
150                
40
30                
50                
150                
a Fluconazole target MIC was defined according to EUCAST susceptibility breakpoints (2 mg/liter). A plus sign indicates that at least 90% of fluconazole PTA is achieved; a minus
sign (shaded) indicates fluconazole PTA attainment failed to achieve 90%.
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function, a standard fluconazole dose of 400 mg daily (6 mg/kg)
resulted in suboptimal exposures, leading to failure in achieving
PK/PD targets (31). The authors suggested that higher fluconazole
doses are required in some patients with higher body weights.
Therefore, individualized weight-based fluconazole dosing is
recommended to ensure PK/PD target achievement. The re-
sults of the aforementioned study support the current study,
which demonstrated that fluconazole at lower dosing failed to
achieve the desired PK/PD in various scenarios. In a population
PK study of fluconazole in critically ill patients receiving con-
tinuous veno-venous hemodiafiltration (CVVHDF), flucona-
zole clearance was higher than previously observed (32). Thus,
this study recommended that higher fluconazole dosing is re-
quired in patients undergoing CVVHDF. The authors recom-
mended a fluconazole loading dose of12 mg/kg followed by a
6-mg/kg maintenance dose. This recommendation matches the
findings of the current study, which showed that patients with
measured CLCR of 150 ml/min (i.e., higher drug clearances)
require higher loading (12 mg/kg) and maintenance (at least 6
mg/kg) doses.
Implications of study findings. Fluconazole remains an im-
portant antifungal drug to prevent and treat Candida spp. infec-
tion. Given the increased prevalence and resistance of non-
albicans Candida infections, critically ill patients, including the
obese and morbidly obese, should be given antifungal therapy to
optimize clinical outcomes as well as to minimize resistance.
EUCAST recommends that a fluconazole PK/PD target of an
fAUC/MIC of
100 be used for high probability of cure. Accord-
ingly, we found that a standard fluconazole dose (200 mg daily)
TABLE 4 FTA at fAUC/MIC of
25 for fluconazole LD (0 to 24 h) at
different BMIs and CLCR for directed therapy (MIC of2 mg/liter)
LD (mg), BMI (kg/m2),
and CLCR (ml/min)
FTA (%)
C. albicans C. tropicalis
200
20
30 99.1 98.7
50 99.1 98. 7
150 98.1 98.4
30
30 99.0 98.0
50 99.2 98.0
150 99.5 98.4
40
30 98.5 96.1
50 98.5 96.0
150 98.0 93.0
400
20
30 99.9 99.5
50 99.9 99.5
150 99.9 99.5
30
30 99.7 99.3
50 99.7 99.2
150 99.9 99.5
40
30 99.5 98.7
50 99.5 98.7
150 99.5 98.6
800
20
30 99.5 99.9
50 99.5 99.9
150 99.5 99.9
30
30 99.9 99.7
50 99.9 99.7
150 99.9 99.9
40
30 99.9 99.5
50 99.9 99.5
150 99.9 99.5
TABLE 5 FTA at fAUC/MIC of 
100 for fluconazole LD (0 to 24 h)
at different BMIs and CLCR for directed therapy (MIC of 2 mg/
liter)
LD (mg), BMI (kg/m2),
and CLCR (ml/min)
FTA (%)a
C. albicans C. tropicalis
200 mg
20
30 94.4 81.9
50 93.6 79.3
150 89.5 65.7
30
30 89.9 68.8
50 89.3 66.8
150 89.5 65.7
40
30 86.1 59.6
50 85.6 58.2
150 80.7 47.3
400 mg
20
30 98.4 95.7
50 98.2 94.7
150 96.6 87.7
30
30 96.7 88.9
50 96.4 87.9
150 96.6 87.7
40
30 94.8 83.3
50 94.5 82.4
150 92.4 75.2
800 mg
20
30 99.5 98.7
50 99.5 98.7
150 99.5 98.4
30
30 99.2 97.8
50 99.2 97.7
150 99.5 98.4
40
30 98.5 96.1
50 98.5 95.8
150 97.7 92.7
a Dose, BMI, and CLCR values that did not achieve the target of fractional target
attainment against at least 90% of isolates are indicated by boldface.
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was insufficient for treatment of susceptible C. albicans and C.
tropicalis in nonobese, obese, and morbidly obese critically ill
patients. Thus, if a fixed dosing approach is to be used, higher
fluconazole doses (400 mg daily or higher) should be consid-
ered for directed therapy. However, therapy for C. albicans and
C. tropicalis might require even higher fluconazole doses (i.e.,
800 mg daily).
When testing a weight-based dosing approach, we found that a
fluconazole loading dose of 12 mg/kg/day followed by a mainte-
nance dose of 6 mg/kg/day achieved PK/PD targets regardless of
patient weight and BMI. This finding results from our observation
that the fluconazole Vc was related to BMI, of which weight is a
central determinant. We also found that fluconazole clearance is
correlated with measured CLCR. Consequently, the fluconazole
maintenance dose should be calculated according to renal func-
tion assessed by measured CLCR.
Study limitations. Although this study is the first population
PK examination of fluconazole in critically ill nonobese, obese,
and morbidly obese patients, it has some limitations we would like
to declare. First, the sample size was relatively small, particularly
for the number of obese and morbidly obese patients, which was
not sufficient for quantifying the effect of fluconazole exposure on
patients’ outcomes. Furthermore, describing all possible correla-
tions between PK parameters and covariates may not have been
possible due to the sample size. Although a larger sample size may
have enabled additional covariate relationships to be demon-
strated, we believe that BMI and measured CLCR are likely to be
the two most significant determinants of dosing. Second, we did
not measure fluconazole plasma concentrations at the site of in-
fection, which may provide better mechanistic data regarding the
effectiveness of dosing. Third, blood samples were collected only
from one dosing interval, and levels may change within patients
over time.
Conclusions. In this study, which included critically ill
obese and morbidly obese patients, we demonstrated that flu-
conazole clearance was correlated with measured CLCR, while
Vc was best correlated with BMI. The results of this study sug-
gest that a higher fixed fluconazole dose (i.e.,400 mg daily) is
required in these patients when they are infected by less sus-
ceptible Candida spp. (MIC of 2 mg/liter). Our results show
that a loading dose of 12 mg/kg followed by a maintenance dose
of 6 or 12 mg/kg/day is required to achieve either the low or
high PK/PD target. Finally, loading doses should be weight
based, whereas maintenance doses should be prescribed ac-
cording to renal function. Further clinical studies of flucona-
zole are warranted to determine the effect of optimized dosing
on clinical outcome.
FIG 3 Probability of target attainment (fAUC/MIC of 100) from 0 to 24 h for
different fluconazole loading doses (milligrams per kilogram) for patients with
a BMI of 30 kg/m2 and CLCR of 50 ml/min. The PK/PD target is achieved when
the value is90% coverage.
FIG 4 Probability of target attainment (fAUC/MIC of 100) from 96 to 120 h for a patient with BMI of 30 kg/m2 at simulated CLCR values of 30, 50, and 150
ml/min and administered different maintenance doses of fluconazole: 3 mg/kg/day (a), 6 mg/kg/day (b), 9 mg/kg/day (c), and 12 mg/kg/day (d). The PK/PD
target is achieved when the value is90% coverage.
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